Josef Puchta

German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany.

Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany.

Helmholtz-Gemeinschaft Deutscher Forschungszentren eV operates as a scientific research organization. It performs cutting-edge research which contributes substantially to solving the grand challenges of science, society, and industry. The firm focuses on six research fields: Energy, Earth and Environment, Health, Key Technologies, Structure of Matter plus Aeronautics, Space, and Transport. It develops research programs for each of these fields. The company was founded in 1995 and is headquartered in Berlin, Germany.